ArticleBMC pregnancy and childbirth2025
APPL1 concentration as a potential biomarker in early-onset preeclampsia: correlations with adiponectin-leptin dysregulation and adverse neonatal outcomes.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPreeclampsia (PE) is a severe pregnancy complication associated with metabolic dysregulation. APPL1 (adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1) is a critical adaptor protein in adiponectin (ADP) and insulin signaling. Its role in preeclampsia (PE) remains underexplored. This study investigates APPL1 as a potential biomarker for early-onset PE and its links to adipokine imbalance, glycolipid metabolism, and neonatal outcomes.
methodsA case-control study enrolled 116 pregnant women (45 PE vs. 71 controls) from a single center. Serum APPL1, ADP, and leptin (LEP) levels of all 116 participants were measured. Glycolipid metabolism indices and neonatal outcomes were collected. The correlation was analyzed by simple linear regression, and the logistic regression was used to evaluate the predictive effects of APPL1, ADP and LEP on PE.
results(1) Prepregnancy BMI (22.15 ± 1.80 vs. 21.03 ± 1.99 kg/m
conclusionsElevated APPL1 is a potential and novel biomarker for early-onset PE, and reflecting adiponectin-leptin dysregulation, glycolipid metabolic disturbances, and adverse neonatal prognosis. Its integration into clinical prediction models warrants further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.